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PECAM-1 is an adhesion molecule — a member of the immunoglobulin super-
family — involved in the transendothelial migration of leukocytes. PECAM-1 is
expressed on lymphocytes, monocytes and granulocytes. It is also found on
endothelial cells and platelets. We present data showing that the cell-bound
form of PECAM-1 expression on monocytes is increased in MS patients, com-
pared to controls. We also show that PECAM-1 is significantly over-expressed on
lymphocytes in patients with active MRI lesions, when compared to those with-
out gadolinium-enhancing lesions. Our results suggest that the cell-bound form
of PECAM-1 can be regarded as a marker of MS activity.
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INTRODUCTION
Multiple sclerosis (MS) is the most frequent de-
myelinating disease of the human central nervous
system (CNS) characterised by perivascular leukocyte
infiltration and inflammation leading to destruction
of the myelin sheaths. Adhesion molecules (AM) me-
diate many cellular processes — they participate in
growth, spreading, homeostasis and wound repair,
as well as leukocyte recruitment and extravasation
to the CNS.
Selectins control the initial weak binding and roll-
ing of leukocytes on endothelium [12], while vascu-
lar cell adhesion molecule 1 (VCAM-1, CD 106) and
intercellular adhesion molecule 1 (ICAM-1, CD54),
both members of the immunoglobulin superfamily,
acting with integrins as their counterparts, the very
late antigen-4 (VLA-4, CD49) and leukocyte function
associated molecule-1 (LFA-1, CD11) respectively,
participate in strong adhesion to endothelium be-
fore extravasation takes place [3]. Another member
of the immunoglobulin superfamily, platelet-endot-
helial cell adhesion molecule-1 (PECAM-1, CD31), also
seems to be involved in leukocyte transmigration
across the blood-brain barrier (BBB). It is mainly seen
within tight intercellular junctions of the endotheli-
um [1]. While ICAM-1 and VCAM-1 have been stud-
ied in patients with demyelinating diseases, PECAM-
-1’s role in pathophysiology remains unclear. Its con-
centration in body fluids exhibits a high level of con-
stitutive expression and is upregulated less upon
cytokine challenge than ICAM-1 or VCAM-1 [4]. Un-
like ICAM-1 and VCAM-1, PECAM-1 is capable of
binding to itself [7]. All of these molecules have two
different forms — native cell–bound (cb), present
on the surface of leukocytes, and soluble, found in
blood and cerebrospinal fluid [8]. The latter are
thought to participate in negative feedback, limit-
ing competitively the adhesion of the cell-bound
forms to their receptors.
Several authors have reported an increased ex-
pression of ICAM-1, LFA-1 and PECAM-1 on microves-
sel endothelium and on the surface of infiltrating
144
Folia Morphol., 2002, Vol. 61, No. 3
mononuclear cells within demyelinating lesions in
experimental allergic encephalitis (EAE), the animal
model of MS [2, 6, 10].
Increased expressions of ICAM-1, VCAM-1 in MS
patients [5] or elevated levels of soluble (s) PECAM-1
[13], sICAM-1 [9] and sVCAM-1 [14, 16, 17] have
also been found.
The goal of this study was to compare the ex-
pression level of the cell-bound forms of PECAM-1
on white blood cells drawn from peripheral blood in
patients with relapsing-remitting (RR) MS with and
without gadolinium-enhancing lesions in MRI.
MATERIAL AND METHODS
14 MS patients with definite RR-MS (age 20–46
years; mean 27 ± 7 years; 10 females and 4 males)
according to Poser’s criteria [15] were studied. All
patients had clearly defined disease relapses with
full recovery or with sequelae and residual deficit
upon recovery. Annual exacerbation rate for studied
patients was 1.2.
The mean disease duration in all MS patients was
5.4 years (range: 5 months – 21 years). Disability was
assessed using the expanded disability status scale
(EDSS) according to Kurtzke [11]. The mean EDSS
was 3.4 (range: 1.0–5.5).
In making the diagnosis, brain MRI, detection of
oligoclonal bands and measurement of intrathecal
IgG synthesis were utilised.
The patients had not received any immunosup-
pressive treatment for at least 1 year or any corti-
costeroids for at least 3 months before inclusion in
the study. The control group consisted of 14 patients
(9 females, 5 males) with diagnosis of tension type
headache and neurasthenia.
Among the 14 studied MS patients, 7 had brain
gadolinium-enhancing lesions apparent in T1-weight-
ed spin echo images (MRI+), and 7 had multiple le-
sions that did not enhance (MRI–). All patients had
oligoclonal bands in the CSF and an elevated IgG
index (1.2 ± 0.4). Control group subjects did not
show oligoclonal bands in the CSF, and had normal
IgG indices (0.5 ± 0.1).
cbPECAM-1 measurement
cbPECAM-1 was measured in peripheral whole
blood; blood was drawn from each patient on the
day of admission; briefly blood was stained with the
antibody (DAKO) directed against human PECAM-1
according to manufacturer’s instructions; then red
blood cells were lysed using FACS Lysing solution
(BECTON DICKINSON); stained leukocytes were anal-
ysed on flow cytometer (Becton Dickinson). Expres-
sion of PECAM-1 was indicated as a percentage of
leukocytes bearing this molecule.
MRI protocol
All patients had MRI performed using a Magne-
ton Impact 1.0 T (Siemens). T1-weighted, proton-
-density, T2-weighted spin echo, as well as gado-
linium-DTPA-enhanced T1 images after administra-
tion of 0.1 mmol/kg gadolinium-DTPA (Schering, Ger-
many). T2-weighted spin echo images of the brain
were done with an echo time (TE) of 80 ms, a repeti-
tion time (TR) of 2200 ms, a 256 ¥ 256 acquisition
matrix, and 5 mm contiguous interleaved slices.
T1-weighted spin echo images were performed us-
ing a TE of 15 ms, a TR of 500 ms a 256 ¥ 256 acqui-
sition matrix and 5 mm contiguous interleaved slices.
Sample collection
Serum and cell free CSF samples were collected
in order to determine IgG and albumin levels, as well
as for oligoclonal bands detection.
Statistical methods
The Statistica statistical program was used. The
Mann-Whitney U test was applied to determine the
significance of differences between subject groups. The
Spearman rank test was used to calculate correlation;
p-values lower than 0.05 were considered significant.
RESULTS
PECAM-1 expression on monocytes was signifi-
cantly higher in the MS group compared to healthy
controls (Table 1). We also observed an increased level
of PECAM-1 expression on lymphocytes in patients
with gadolinium-enhancing lesions in MRI compared
to those without active plaques (Table 2). Mean IgG
Table 1. PECAM-1 expression on monocytes in MS
patients and control group
RR-MS Controls P
(n = 14) (MS patients vs. controls)
PECAM-1 95 ± 4% 81 ± 26% 0.04
on monocytes
Table 2. PECAM-1 expression on lymphocytes in MS
patients with and without gadolinium enhancing lesions
MRI+ (n = 7) MRI– (n = 7) P
PECAM-1 on lymphocytes 50 ± 3% 31 ± 3.5% 0.003
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CSF level in MS group was 5.7 ± 3.1 mg% and in
controls 2.1 ± 0.4. Mean IgG index in MS group was
1.2 ± 0.6 and in the control group 0.5 ± 0.1.
DISCUSSION
In the present study we found increased expres-
sion of PECAM-1 on monocytes in MS patients com-
pared to controls. This finding suggests that immu-
nological pathology in MS might not be restrained
to lymphocyte population. Our finding is concordant
with the observations of Shaw et al. [18], who found
that blocking the monoclonal antibody to PECAM-1
significantly reduced monocyte transmigration
through the blood-brain barrier, demonstrating that
it retains a functional role even though its levels were
reduced and redistributed away from junctions af-
ter incubation with interferon gamma or tumour
necrosis factor. Neutrophil migration in the same
study, however, was not affected by reduction of
PECAM-1 density within intercellular junctions. This
demonstrates that PECAM-1 might play a pivotal role
not only for lymphocyte but also for monocyte trans-
migration across the blood-brain barrier.
This study is the first to show a significant in-
crease in cbPECAM-1 on lymphocytes in MS patients
with gadolinium-enhancing lesions. It is consistent
with our previous report [13] emphasising the ele-
vation of soluble PECAM-1 level in sera of patients
with active disease. Our findings would require
a subsequent PECAM mRNA expression analysis.
Since PECAM-1 expression on lymphocytes is aug-
mented in subjects with gadolinium-enhancing le-
sions and in MS patients compared to normal con-
trols, it should be expected that its soluble form con-
centration is also increased, which has been demon-
strated. Thus, it might be considered a marker of
disease activity.
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